YTHDF2 and neoplasm: The small molecule inhibitor DC‐Y13‐27, identified through screening and targeting YTHDF2, can overcome MDSC‐induced immunosuppression and improve the efficacy of IR and/or anti‐PD‐L1 combination therapy, offering a new combined treatment strategy for tumour immunotherapy.188